LE WE PMID CA
Parkinson s disease1829Parkinson Erkrankung

Alzheimer s disease

Amyloid precursor protein

Anandamide

Androgens (Hypogonadotropic hypogonadism)

ATP13A2

Autonomous nervous system (Autonomic neuropathy)

Autophagy

Basal ganglia

Bioinformatics

Carbonyl cyanide m chlorophenylhydrazone CCCP

Cleft plate

CNS (Astrocyte)

CNS (Cerebral cortex)

CNS (Deep brain stimulation)

CNS (Electrotherapy)

CNS (Extrapyramidal diseases)

CNS (Stroke BASKET)

Cognitive behavior therapy

Cybrid

DJ1

Drooling

Dyskinesia (tardive)

Entacapone

FGF Fibroblast growth factor

FGF10

FGF14

FGF20

FGF23

FGF3

FGF8

FGF9

Glucocorticoids

Gluconeogenesis

HtrA2 Omi

Hypophosphatemic ricketts

Lacrimo auriculo dento digital syndrome

Levodopa

Lewy body

LRRK2

Manganese

Methamphetamin

Michel aplasia

Mitochondria (BASKET)

Mitochondria (Dysfunction)

Mitochondria (Fission and Fusion)

Mitochondria (Uncoupling)

Mitophagy

MPTP

Multiple sclerosis

Multiple system atrophy

Neurodegeneration

Neuronal network (Neurophysiology)

Pallidotomy

Parkinson s disease

Pesticides

PINK1

Pramipexole

PRKN

Progressive supranuclear palsy

Quetiapine

Rasagiline

Regeneration of tissues and other biologic structures

Rivastigmin

Ropinirole

Salivary gland (Malformation)

Simulation of biological processes (Bioinformatics)

SNCA

Spinocerebellar ataxia

Statin

Synuclein

Tolcapone

Tremor (BASKET)

TRPV1

Uric acid

Zonisamide

1995  
1
Drug treatment of Parkinson's disease.
[7888935] BMJ 310(6979): 575-9 (1995)
1996  
2
Drug therapy for Parkinson's disease.
[8790306] South Med J 89(9): 851-6 (1996)
2005  
3
Parkinson's disease: the first common neurological disease due to auto-intoxication?
[15728403] QJM 98(3): 215-26 (2005)
2005  
4
Parkinson's disease: aetiology, diagnosis, and management.
[16340025] Hong Kong Med J 11(6): 476-89 (2005)
2007  
5
Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
[17471304] Acta Med Okayama 61(2): 51-6 (2007)
2002  
6
Catechol-O-methyltransferase and Parkinson's disease.
[11873938] Acta Med Okayama 56(1): 1-6 (2002)
2008  
7
Parkinson disease: not just a movement disorder.
[19088004] Cleve Clin J Med 75(12): 856-64 (2008)
2007  
8
Parkinson disease: managing a complex, progressive disease at all stages.
[17506237] Cleve Clin J Med 74(5): 313-4, 317-8, 320-2 passim (2007)
2006  
9
Utility of tolcapone in fluctuating Parkinson's disease.
[18046910] Clin Interv Aging 1(4): 317-25 (2006)
2006  
10
Approach to diagnosis of Parkinson disease.
[16893149] Can Fam Physician 52(): 862-8 (2006)
2006  
11
Parkinson disease. Changing concepts and treatments.
[16893139] Can Fam Physician 52(-): 829-30, 835-6 (2006)
2009  
12
Update on ropinirole in the treatment of Parkinson's disease.
[19557097] Neuropsychiatr Dis Treat 5(-): 33-6 (2009)
2008  
13
Current approaches to the treatment of Parkinson's disease.
[19043519] Neuropsychiatr Dis Treat 4(4): 743-57 (2008)
2008  
14
Update on the use of pramipexole in the treatment of Parkinson's disease.
[18728740] Neuropsychiatr Dis Treat 4(2): 337-52 (2008)
2008  
15
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.
[18728767] Neuropsychiatr Dis Treat 4(1): 1-9 (2008)
2007  
16
Rivastigmine for the treatment of dementia associated with Parkinson's disease.
[19300613] Neuropsychiatr Dis Treat 3(6): 775-83 (2007)
2006  
17
Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
[17015225] Neuron 52(1): 33-8 (2006)
2003  
18
Parkinson's disease: mechanisms and models.
[12971891] Neuron 39(6): 889-909 (2003)
2001  
19
Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions.
[11530892] Neural Plast 8(1-2): 99-110 (2001)
2009  
20
Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease.
[19780902] J Neurochem 111(5): 1075-93 (2009)
2008  
21
Mitochondrial alterations in Parkinson's disease: new clues.
[18680555] J Neurochem 107(2): 317-28 (2008)
2006  
22
Modifications of the iron-neuromelanin system in Parkinson's disease.
[16417570] J Neurochem 96(4): 909-16 (2006)
1998  
23
Neurochemical and neurogenetic correlates of Parkinson's disease.
[9721714] J Neurochem 71(3): 893-902 (1998)
2007  
24
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
[17894650] CNS Drug Rev 13(3): 352-79 (2007)
2008  
25
Impulse-control disorders in Parkinson's disease.
[18704024] CNS Spectr 13(8): 690-8 (2008)
2007  
26
Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease.
[17426665] CNS Spectr 12(4): 275-86 (2007)
2006  
27
Non-motor aspects of Parkinson's disease.
[16816793] CNS Spectr 11(7): 541-54 (2006)
2006  
28
Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders.
[16816792] CNS Spectr 11(7): 521-36 (2006)
2009  
29
The emerging role of autophagy in Parkinson's disease.
[19754977] Mol Brain 2(): 29 (2009)
2007  
30
The 6-hydroxydopamine model of Parkinson's disease.
[17449457] Neurotox Res 11(3-4): 151-67 (2007)
2007  
31
Inflammation as a causative factor in the aetiology of Parkinson's disease.
[17339843] Br J Pharmacol 150(8): 963-76 (2007)
2000  
32
The parkinsonian models: invertebrates to mammals.
[11138723] Jpn J Pharmacol 84(3): 237-43 (2000)
2010  
33
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.
[20694135] Core Evid 5(-): 1-10 (2010)
2008  
34
Progress in the pathogenesis and genetics of Parkinson's disease.
[18426756] Philos Trans R Soc Lond B Biol Sci 363(1500): 2215-27 (2008)
2010  
35
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
[20423607] BMB Rep 43(4): 233-44 (2010)
2010  
36
The role of neuroinflammation on the pathogenesis of Parkinson's disease.
[20423606] BMB Rep 43(4): 225-32 (2010)
2008  
37
Parkinson's disease--Part 3: Neuropsychiatric symptoms.
[18402509] Am J Manag Care 14(2 Suppl): S59-69 (2008)
2008  
38
Parkinson's disease--Part 2: Treatment of motor symptoms.
[18402508] Am J Manag Care 14(2 Suppl): S49-58 (2008)
2008  
39
Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
[18402507] Am J Manag Care 14(2 Suppl): S40-8 (2008)
2003  
40
2008  
41
A critical evaluation of the Braak staging scheme for Parkinson's disease.
[19067353] Ann Neurol 64(5): 485-91 (2008)
2008  
42
Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
[19064744] Arch Neurol 65(12): 1577-81 (2008)
2006  
43
Phenotypic commonalities in familial and sporadic Parkinson disease.
[16606772] Arch Neurol 63(4): 579-83 (2006)
2006  
44
Implications of genetics on the diagnosis and care of patients with Parkinson disease.
[16533959] Arch Neurol 63(3): 328-34 (2006)
2005  
45
Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease.
[16157740] Arch Neurol 62(9): 1343-4 (2005)
2005  
46
Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return?
[15824249] Arch Neurol 62(4): 533-6 (2005)
2005  
47
Molecular pathogenesis of Parkinson disease.
[15767499] Arch Neurol 62(3): 353-7 (2005)
2004  
48
Initial Parkinson disease therapy: levodopa, dopamine agonists, or both?
[15596625] Arch Neurol 61(12): 1972-3 (2004)
2004  
49
Dopamine agonists modify the course of Parkinson disease.
[15596624] Arch Neurol 61(12): 1969-71 (2004)
2004  
50
Initial treatment of Parkinson disease: levodopa or dopamine agonists.
[15596623] Arch Neurol 61(12): 1966-9 (2004)
2001  
51
Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation.
[11735770] Arch Neurol 58(12): 1970-2 (2001)
2001  
52
Subthalamic deep brain stimulation: neurobehavioral concerns.
[11493159] Arch Neurol 58(8): 1205-6 (2001)
2000  
53
Surgery for Parkinson disease: A critical evaluation of the state of the art.
[10927791] Arch Neurol 57(8): 1118-25 (2000)
1999  
54
Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion.
[10488806] Arch Neurol 56(9): 1064-9 (1999)
1999  
55
New and emerging therapies for Parkinson disease.
[10404979] Arch Neurol 56(7): 785-90 (1999)
1999  
56
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.
[10328247] Arch Neurol 56(5): 529-35 (1999)
1999  
57
Diagnostic criteria for Parkinson disease.
[9923759] Arch Neurol 56(1): 33-9 (1999)
2008  
58
Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease.
[18216494] Autophagy 4(3): 372-4 (2008)
2008  
59
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease.
[18187492] Brain 131(Pt 8): 1969-78 (2008)
2004  
60
Biomarkers and Parkinson's disease.
[15215212] Brain 127(Pt 8): 1693-705 (2004)
2000  
61
The pedunculopontine nucleus and Parkinson's disease.
[10960043] Brain 123 ( Pt 9)(-): 1767-83 (2000)
1999  
62
Neuropsychological outcome following unilateral pallidotomy.
[10581217] Brain 122 ( Pt 12)(-): 2209-20 (1999)
1999  
63
Unilateral pallidotomy for advanced Parkinson's disease.
[10094248] Brain 122 ( Pt 3)(-): 381-2 (1999)
1964  
64
CRYOTHALAMECTOMY FOR PARKINSON'S DISEASE.
[14201235] Calif Med 101(-): 248-52 (1964)
1969  
65
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
[4903690] Can Med Assoc J 101(13): 59-68 (1969)
2007  
66
Mitochondrial dysfunction in Parkinson's disease.
[17464321] Cell Death Differ 14(7): 1261-6 (2007)
1998  
67
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
[10203692] Cell Death Differ 5(10): 832-7 (1998)
2004  
68
How does parkin ligate ubiquitin to Parkinson's disease?
[15229644] EMBO Rep 5(7): 681-5 (2004)
2008  
69
Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
[18535172] Exp Biol Med (Maywood) 233(8): 941-51 (2008)
2008  
70
Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease.
[19021754] FEBS J 275(23): 5767-73 (2008)
2005  
71
Molecular pathogenesis of Parkinson's disease.
[16126732] Hum Mol Genet 14(18): 2749-55 (2005)
2004  
72
Parkin genetics: one model for Parkinson's disease.
[14976155] Hum Mol Genet 13 Spec No 1(-): R127-33 (2004)
2002  
73
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.
[12351575] Hum Mol Genet 11(20): 2395-407 (2002)
1999  
74
The genetics of disorders with synuclein pathology and parkinsonism.
[10469843] Hum Mol Genet 8(10): 1901-5 (1999)
1995  
75
Parkinson's disease: from etiology to treatment.
[8774962] Intern Med 34(11): 1045-54 (1995)
2005  
76
Subthalamic stimulation for Parkinson's disease.
[16011063] Isr Med Assoc J 7(7): 458-63 (2005)
2006  
77
Diagnosis and treatment of Parkinson disease: molecules to medicine.
[16823471] J Clin Invest 116(7): 1744-54 (2006)
2005  
78
STN stimulation and neuroprotection in Parkinson's disease--when beautiful theories meet ugly facts.
[16107346] J Neurol Neurosurg Psychiatry 76(9): 1186-7 (2005)
2005  
79
Neurodegenerative disorders: Parkinson's disease and Huntington's disease.
[16024878] J Neurol Neurosurg Psychiatry 76(8): 1058-63 (2005)
2005  
80
Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
[15965192] J Neurol Neurosurg Psychiatry 76(7): 903-4 (2005)
2005  
81
Beyond the holy grail of motor symptoms: deep brain stimulation for Parkinson's disease.
[15897490] J Neurol Neurosurg Psychiatry 76(6): 759-60 (2005)
2005  
82
Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement.
[15716537] J Neurol Neurosurg Psychiatry 76(3): 409-14 (2005)
2004  
83
Early pathological changes in the parkinsonian brain.
[14966144] J Neurol Neurosurg Psychiatry 75(3): 352 (2004)
2000  
84
Dopamine agonists: their role in the treatment of Parkinson's disease.
[10811688] J Neurol Neurosurg Psychiatry 68(6): 685-9 (2000)
1997  
85
1996  
86
How far are we in understanding the cause of Parkinson's disease?
[8676157] J Neurol Neurosurg Psychiatry 61(1): 4-16 (1996)
1994  
87
1989  
88
1989  
89
Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
[2666576] J Neurol Neurosurg Psychiatry Suppl(-): 22-8 (1989)
1989  
90
1989  
91
Current theories on the cause of Parkinson's disease.
[2666574] J Neurol Neurosurg Psychiatry Suppl(-): 13-7 (1989)
1981  
92
Speech disorders of Parkinsonism: a review.
[7031185] J Neurol Neurosurg Psychiatry 44(9): 751-8 (1981)
2001  
93
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
[11724917] Mol Pathol 54(6): 414-8 (2001)
2001  
94
The aetiology of idiopathic Parkinson's disease.
[11724911] Mol Pathol 54(6): 369-80 (2001)
2004  
95
Neuroimaging in Parkinson's disease.
[15717025] NeuroRx 1(2): 243-54 (2004)
2004  
96
Genetics of Parkinson disease.
[15717024] NeuroRx 1(2): 235-42 (2004)
2004  
97
Neurodegeneration and neuroprotection in Parkinson disease.
[15717014] NeuroRx 1(1): 139-54 (2004)
2004  
98
Molecules that cause or prevent Parkinson's disease.
[15547643] PLoS Biol 2(11): e401 (2004)
2004  
99
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
[15299154] Postgrad Med J 80(946): 452-8 (2004)
2003  
100
Neuropsychiatric non-motor aspects of Parkinson's disease.
[14612597] Postgrad Med J 79(936): 561-5 (2003)
2000  
101
Pharmacological treatment of Parkinson's disease.
[11009573] Postgrad Med J 76(900): 602-10 (2000)
1997  
102
1992  
103
1988  
104
Accuracy in the clinical diagnosis of parkinsonian syndromes.
[3059338] Postgrad Med J 64(751): 345-51 (1988)
1977  
105
The treatment of Parkinson's disease.
[343079] Postgrad Med J 53(626): 729-31 (1977)
1977  
106
1977  
107
Physiology of abnormal movements.
[343077] Postgrad Med J 53(626): 713-8 (1977)
1977  
108
The biochemistry of the basal ganglia and Parkinson's disease.
[24209] Postgrad Med J 53(626): 719-25 (1977)
1972  
109
Augmenting the action of levodopa.
[4568331] Postgrad Med J 48(565): 653-6 (1972)
1971  
110
Current concepts of Parkinsonism.
[4945017] Postgrad Med J 47(554): 794-9 (1971)
1996  
111
Parkinson's disease. Diagnosis and treatment.
[8987437] West J Med 165(4): 234-40 (1996)
1994  
112
Treatment of Parkinson's disease.
[7975571] West J Med 161(3): 303-8 (1994)
1974  
113
Parkinson's disease and levodopa. A five-year follow-up and review.
[4606887] West J Med 121(3): 188-206 (1974)
2003  
114
Are ubiquitination pathways central to Parkinson's disease?
[12859888] Cell 114(1): 1-8 (2003)
2004  
115
alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
[15135042] FEBS Lett 565(1-3): 1-5 (2004)
2008  
116
Visual signs and symptoms of Parkinson's disease.
[18271776] Clin Exp Optom 91(2): 129-38 (2008)
2004  
117
CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
[14767563] Int J Mol Med 13(3): 343-53 (2004)
2006  
118
Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease.
[16953112] Exp Mol Med 38(4): 333-47 (2006)
2006  
119
Recognition and management of neuropsychiatric complications in Parkinson's disease.
[17146092] CMAJ 175(12): 1545-52 (2006)
2003  
120
Current concepts in the diagnosis and management of Parkinson's disease.
[12566335] CMAJ 168(3): 293-301 (2003)
2011  
121
Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.
[21731080] Acta Neurobiol Exp (Wars) 71(2): 269-80 (2011)
2008  
122
Animal models of Parkinson's disease progression.
[18273623] Acta Neuropathol 115(4): 385-98 (2008)
2009  
123
Neuropsychiatry of Parkinson's disease.
[19838536] Arq Neuropsiquiatr 67(3B): 930-9 (2009)
2011  
124
Positron emission tomography neuroimaging in Parkinson's disease.
[21904653] Am J Transl Res 3(4): 323-41 (2011)
2007  
125
2010  
126
Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism.
[19595762] Biochim Biophys Acta 1802(1): 20-8 (2010)
2010  
127
Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.
[19619643] Biochim Biophys Acta 1802(1): 11-9 (2010)
2008  
128
Redox imbalance in Parkinson's disease.
[18358848] Biochim Biophys Acta 1780(11): 1362-7 (2008)
2010  
129
Towards model-based control of Parkinson's disease.
[20368246] Philos Transact A Math Phys Eng Sci 368(1918): 2269-308 (2010)
2009  
130
Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease.
[20035637] Chang Gung Med J 32(6): 589-99 (2009)
2009  
131
Methamphetamine-induced neurotoxicity: the road to Parkinson's disease.
[20081231] Pharmacol Rep 61(6): 966-77 (2009)
2005  
132
Present and future drug treatment for Parkinson's disease.
[16227533] J Neurol Neurosurg Psychiatry 76(11): 1472-8 (2005)
2004  
133
Use and interpretation of on/off diaries in Parkinson's disease.
[14966154] J Neurol Neurosurg Psychiatry 75(3): 396-400 (2004)
2007  
134
Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease.
[17563240] Expert Rev Neurother 7(6): 585-9 (2007)
2008  
135
CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach.
[18088199] Expert Rev Neurother 8(1): 27-35 (2008)
2010  
136
Parkinson's disease: insights from pathways.
[20421364] Hum Mol Genet 19(R1): R21-7 (2010)
2007  
137
2010  
138
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
[20852670] Clin Interv Aging 5(-): 229-38 (2010)
2010  
139
The role of rasagiline in the treatment of Parkinson's disease.
[20517484] Clin Interv Aging 5(-): 149-56 (2010)
2010  
140
Imaging approaches to Parkinson disease.
[20351351] J Nucl Med 51(4): 596-609 (2010)
2010  
141
Astrocytes and therapeutics for Parkinson's disease.
[20880505] Neurotherapeutics 7(4): 413-23 (2010)
2009  
142
LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles.
[19804414] FEBS J 276(22): 6445-54 (2009)
2008  
143
Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease.
[18342017] Free Radic Biol Med 44(11): 1873-86 (2008)
2011  
144
Available and emerging treatments for Parkinson's disease: a review.
[21607020] Drug Des Devel Ther 5(-): 241-54 (2011)
2009  
145
The retina in Parkinson's disease.
[19336464] Brain 132(Pt 5): 1128-45 (2009)
2004  
146
Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies.
[15038467] Can J Neurol Sci 31(1): 7-21 (2004)
2010  
147
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
[20945982] Biomark Med 4(5): 701-12 (2010)
2011  
148
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.
[21654875] Neuropsychiatr Dis Treat 7(-): 297-302 (2011)
2008  
149
Drugs for Parkinson’s disease: levodopa is still the gold standard.
[18728800] Neuropsychiatr Dis Treat 4(1): i-ii (2008)
2009  
150
From genes to proteins in mendelian Parkinson's disease: an overview.
[19943343] Anat Rec (Hoboken) 292(12): 1893-901 (2009)
2010  
151
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
[20837848] Arch Neurol 67(9): 1062-7 (2010)
2005  
152
Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro.
[15659603] J Neurosci 25(3): 662-71 (2005)
2010  
153
Quetiapine in the treatment of psychosis in Parkinson's disease.
[21179595] Ther Adv Neurol Disord 3(6): 339-50 (2010)
2010  
154
Pharmacotherapy in Parkinson's disease: case studies.
[21179604] Ther Adv Neurol Disord 3(2): 117-26 (2010)
2010  
155
Treatment of dysautonomia in extrapyramidal disorders.
[21180636] Ther Adv Neurol Disord 3(1): 53-67 (2010)
2009  
156
Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.
[21180645] Ther Adv Neurol Disord 2(2): 105-13 (2009)
2009  
157
Cellular repair strategies in Parkinson's disease.
[21180641] Ther Adv Neurol Disord 2(1): 51-60 (2009)
2009  
158
A review of the use of zonisamide in Parkinson's disease.
[21180621] Ther Adv Neurol Disord 2(5): 313-7 (2009)
2009  
159
Targeting the progression of Parkinson's disease.
[19721815] Curr Neuropharmacol 7(1): 9-36 (2009)
2009  
160
Parkinson disease: systemic and orofacial manifestations, medical and dental management.
[19491161] J Am Dent Assoc 140(6): 658-69 (2009)
2008  
161
Genetic neuropathology of Parkinson's disease.
[18784814] Int J Clin Exp Pathol 1(3): 217-31 (2008)
2008  
162
Diagnosis and management of Parkinson's disease dementia.
[18822028] Int J Clin Pract 62(10): 1581-7 (2008)
2010  
163
Prevalence, classification, and etiology of pain in Parkinson's disease: association between Parkinson's disease and fibromyalgia or chronic widespread pain.
[20805678] Tohoku J Exp Med 222(1): 1-5 (2010)
2011  
164
Manganese and Parkinson's disease: a critical review and new findings.
[22124833] Cien Saude Colet 16(11): 4519-66 (2011)
2011  
165
Clinical problems in the hospitalized Parkinson's disease patient: systematic review.
[21284037] Mov Disord 26(2): 197-208 (2011)
2011  
166
Rapidly progressive diffuse Lewy body disease.
[21484863] Mov Disord 26(7): 1316-23 (2011)
2010  
167
DJ-1, PINK1, and their effects on mitochondrial pathways.
[20187230] Mov Disord 25 Suppl 1(-): S44-8 (2010)
2008  
168
2009  
169
Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.
[19298613] CNS Neurosci Ther 15(2): 157-82 (2009)
2011  
170
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines.
[21159538] Parkinsonism Relat Disord 17(3): 139-45 (2011)
2011  
171
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.
[21423589] Patient Prefer Adherence 5(-): 57-64 (2011)
2008  
172
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
[18665659] Drugs Aging 25(8): 665-82 (2008)
2010  
173
2008  
174
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
[17680806] Genes Brain Behav 7(2): 129-51 (2008)
2004  
175
A reality test: How well do we understand psychosis in Parkinson's disease?
[14990754] J Neuropsychiatry Clin Neurosci 16(1): 8-18 (2004)
2009  
176
The cybrid model of sporadic Parkinson's disease.
[19328199] Exp Neurol 218(2): 320-5 (2009)
2009  
177
Mitochondrial dynamics in Parkinson's disease.
[19332061] Exp Neurol 218(2): 247-56 (2009)
2010  
178
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.
[19913097] Neurobiol Dis 37(3): 510-8 (2010)
2010  
179
A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD.
[20921515] Neurology 75(14): 1292-9 (2010)
2010  
180
Persistent organochlorine pesticides in serum and risk of Parkinson disease.
[20350979] Neurology 74(13): 1055-61 (2010)
2010  
181
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
[20368634] Neurology 74(14): 1143-8 (2010)
2011  
182
Prospects of statins in Parkinson disease.
[21252380] Neuroscientist 17(3): 244-55 (2011)
2010  
183
Unravelling the role of defective genes.
[20696314] Prog Brain Res 183(-): 43-57 (2010)
2010  
184
Pathophysiological roles for purines: adenosine, caffeine and urate.
[20696321] Prog Brain Res 183(-): 183-208 (2010)
2010  
185
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
[20696322] Prog Brain Res 183(-): 209-33 (2010)
2010  
186
Genetic animal models of Parkinson's disease.
[20547124] Neuron 66(5): 646-61 (2010)
2010  
187
Parkinson's disease as a disconnection syndrome.
[20383586] Neuropsychol Rev 20(2): 191-208 (2010)
2005  
188
Neuroimaging and therapeutics in movement disorders.
[15897956] NeuroRx 2(2): 361-71 (2005)
2005  
189
Genetic mouse models of parkinsonism: strengths and limitations.
[16389313] NeuroRx 2(3): 495-503 (2005)
2005  
190
Toxin-induced models of Parkinson's disease.
[16389312] NeuroRx 2(3): 484-94 (2005)
2009  
191
Prevalence and definition of drooling in Parkinson's disease: a systematic review.
[19288042] J Neurol 256(9): 1391-6 (2009)
2011  
192
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
[21244648] Mol Neurodegener 6(1): 6 (2011)
2010  
193
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.
[20388210] Mol Neurodegener 5(-): 14 (2010)
2011  
194
Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.
[21772815] Front Syst Neurosci 5(-): 49 (2011)
2011  
195
Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.
[21615738] J Neurochem 118(3): 326-38 (2011)
2007  
196
Mitochondrial dysfunction in Parkinson's disease--revisited.
[17530578] Neurol Neurochir Pol 41(2): 150-9 (2007)
2010  
197
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.
[20577640] Front Aging Neurosci 2(-): 17 (2010)
2011  
198
Treatment of advanced Parkinson's disease.
[21331376] Parkinsons Dis 2010(-): 480260 (2011)
2011  
199
The endotoxin-induced neuroinflammation model of Parkinson's disease.
[21331154] Parkinsons Dis 2011(-): 487450 (2011)
2011  
200
New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.
[21403865] Parkinsons Dis 2011(-): 675630 (2011)
2011  
201
Models for LRRK2-Linked Parkinsonism.
[21603132] Parkinsons Dis 2011(-): 942412 (2011)
2011  
202
Lipopolysaccharide animal models for Parkinson's disease.
[21603177] Parkinsons Dis 2011(-): 327089 (2011)
2011  
203
Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.
[21603178] Parkinsons Dis 2011(-): 393769 (2011)
2011  
204
Optimizing a rodent model of Parkinson's disease for exploring the effects and mechanisms of deep brain stimulation.
[21603182] Parkinsons Dis 2011(-): 414682 (2011)
2011  
205
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
[21603186] Parkinsons Dis 2011(-): 689181 (2011)
2011  
206
Mitochondrial contribution to Parkinson's disease pathogenesis.
[21687805] Parkinsons Dis 2011(-): 159160 (2011)
2011  
207
Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson's disease.
[21860779] Parkinsons Dis 2011(-): 979231 (2011)
2010  
208
Feasibility of using cranial electrotherapy stimulation for pain in persons with Parkinson's disease.
[20976091] Parkinsons Dis 2010(-): 569154 (2010)
2011  
209
Parkinson's disease mouse models in translational research.
[21559878] Mamm Genome 22(7-8): 401-19 (2011)
2009  
210
Molecular pathology of the fibroblast growth factor family.
[19621416] Hum Mutat 30(9): 1245-55 (2009)
2009  
211
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.
[19165601] Apoptosis 14(4): 478-500 (2009)
2009  
212
Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics.
[19967437] J Bioenerg Biomembr 41(6): 487-91 (2009)
2009  
213
Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.
[20012177] J Bioenerg Biomembr 41(6): 473-9 (2009)
2010  
214
Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?
[21126348] BMC Med 8(): 80 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Parkinson-Syndrome, Diagnostik und Therapie


  • Search PubMed and many other databases on the combined search terms

    GG: parkinson disease
    GG: parkinson's disease

  • Parkinson Erkrankung

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia